Innovations and Challenges in Renal Cancer: Summary Statement From the Third Cambridge Conference

被引：13

作者：

Atkins, Michael B. ^{[1
]}

Bukowski, Ronald M. ^{[2
]}

Escudier, Bernard J. ^{[3
]}

Figlin, Robert A. ^{[4
]}

Hudes, Gary H. ^{[5
]}

Kaelin, William G., Jr. ^{[6
]}

Linehan, W. Marston ^{[7
]}

McDermott, David F. ^{[1
]}

Mier, James W. ^{[1
]}

Pedrosa, Ivan ^{[1
]}

Rini, Brian I. ^{[2
]}

Signoretti, Sabina ^{[8
]}

Sosman, Jeffrey A. ^{[9
]}

Teh, Bin Tean ^{[10
]}

Wood, Christopher G. ^{[11
]}

Zurita, Amado J. ^{[11
]}

King, Laura ^{[12
]}

机构：

[1] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA

[2] Cleveland Clin Fdn, Taussig Canc Inst, Cleveland, OH 44195 USA

[3] Inst Gustave Roussy, Unite Immunotherapie, Villejuif, France

[4] City Hope Comprehens Canc Ctr, Duarte, CA USA

[5] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA

[6] Howard Hughes Med Inst, Boston, MA 02115 USA

[7] NCI, Bethesda, MD 20892 USA

[8] Brigham & Womens Hosp, Boston, MA 02115 USA

[9] Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[10] Van Andel Res Inst, Grand Rapids, MI USA

[11] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[12] InforMED Commun Inc, Carlisle, MA USA

来源：

CANCER | 2009年 / 115卷 / 10期

关键词：

renal cancer; genetics; vascular endothelial growth factor; immunotherapy; biomarkers; IDENTIFICATION; INTERLEUKIN-2;

D O I：

10.1002/cncr.24229

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The Third Cambridge Conference on Innovations and Challenges in Renal Cancer, a symposium held in Cambridge, Massachusetts, June 27-28, 2008, and chaired by Michael B. Atkins, was convened to discuss the current state of knowledge in the field, critique new data, stimulate communication among those involved in basic and clinical research, and offer recommendations for further study. Four main topics were discussed: genetics and molecular biology of renal cell cancer, staging and prognosis, systemic therapy, and correlative science and biomarkers in stage IV disease. The conference format combined brief presentations with extended periods of discussion. The conclusions and recommendations are summarized in this paper and presented in more detail in the individual papers that follow. Cancer 2009;115(10 suppl):2247-51. (C) 2009 American Cancer Society.

引用

页码：2247 / 2251

页数：5

共 15 条

[11]

Rini BI, 2007, J CLIN ONCOL, V25

[12] Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2 - Identification of the antigens mediating response [J].

Rosenberg, SA ;

Yang, JC ;

White, DE ;

Steinberg, SM .

ANNALS OF SURGERY, 1998, 228 (03) :307-317

[13]

Sabo E, 2001, CLIN CANCER RES, V7, P533

[14] Renal Cell Carcinoma: Dynamic Contrast-enhanced MR Imaging for Differentiation of Tumor Subtypes-Correlation with Pathologic Findings [J].

Sun, Maryellen R. M. ;

Ngo, Long ;

Genega, Elizabeth M. ;

Atkins, Michael B. ;

Finn, Myra E. ;

Rofsky, Neil M. ;

Pedrosa, Ivan .

RADIOLOGY, 2009, 250 (03) :793-802

[15] A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer [J].

Yang, JC ;

Haworth, L ;

Sherry, RM ;

Hwu, P ;

Schwartzentruber, DJ ;

Topalian, SL ;

Steinberg, SM ;

Chen, HX ;

Rosenberg, SA .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (05) :427-434

← 1 2 →